JPWO2020146432A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020146432A5
JPWO2020146432A5 JP2021539400A JP2021539400A JPWO2020146432A5 JP WO2020146432 A5 JPWO2020146432 A5 JP WO2020146432A5 JP 2021539400 A JP2021539400 A JP 2021539400A JP 2021539400 A JP2021539400 A JP 2021539400A JP WO2020146432 A5 JPWO2020146432 A5 JP WO2020146432A5
Authority
JP
Japan
Prior art keywords
antibody
car
cell
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518150A (ja
JP2022518150A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012637 external-priority patent/WO2020146432A1/en
Publication of JP2022518150A publication Critical patent/JP2022518150A/ja
Publication of JPWO2020146432A5 publication Critical patent/JPWO2020146432A5/ja
Publication of JP2022518150A5 publication Critical patent/JP2022518150A5/ja
Priority to JP2025061674A priority Critical patent/JP2025111482A/ja
Pending legal-status Critical Current

Links

Images

JP2021539400A 2019-01-07 2020-01-07 細胞療法での抗ｃｄ４５抗体－薬物結合体（ａｄｃ）の使用経験 Pending JP2022518150A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061674A JP2025111482A (ja) 2019-01-07 2025-04-03 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962789462P 2019-01-07 2019-01-07
US62/789,462 2019-01-07
US201962845829P 2019-05-09 2019-05-09
US62/845,829 2019-05-09
PCT/US2020/012637 WO2020146432A1 (en) 2019-01-07 2020-01-07 Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061674A Division JP2025111482A (ja) 2019-01-07 2025-04-03 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用

Publications (3)

Publication Number Publication Date
JP2022518150A JP2022518150A (ja) 2022-03-14
JPWO2020146432A5 true JPWO2020146432A5 (https=) 2023-01-19
JP2022518150A5 JP2022518150A5 (https=) 2023-01-19

Family

ID=71520485

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539400A Pending JP2022518150A (ja) 2019-01-07 2020-01-07 細胞療法での抗ｃｄ４５抗体－薬物結合体（ａｄｃ）の使用経験
JP2025061674A Pending JP2025111482A (ja) 2019-01-07 2025-04-03 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061674A Pending JP2025111482A (ja) 2019-01-07 2025-04-03 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用

Country Status (7)

Country Link
US (1) US20220062339A1 (https=)
EP (1) EP3908296A4 (https=)
JP (2) JP2022518150A (https=)
CN (1) CN113490504A (https=)
AU (1) AU2020206117A1 (https=)
CA (1) CA3125751A1 (https=)
WO (1) WO2020146432A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022040088A2 (en) * 2020-08-21 2022-02-24 Synthekine, Inc. Cd45 binding molecules and methods of use
GB202015226D0 (en) * 2020-09-25 2020-11-11 Adc Therapeutics S A Pyrrol obenzodiazepine-antibody conugates and uses thereof
GB202015235D0 (en) 2020-09-25 2020-11-11 Ucl Business Plc Anti-CD45 antibodies and related therapeutics
WO2022081486A1 (en) * 2020-10-12 2022-04-21 Sorrento Therapeutics, Inc. Cd19-directed chimeric antigen receptor constructs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
HK1249534A1 (zh) * 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
IL295224B2 (en) * 2015-05-28 2025-07-01 Kite Pharma Inc Methods of conditioning patients for t cell therapy
CN107708741A (zh) * 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
ES2887273T3 (es) * 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
CA3117367A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Anti-cd45 antibodies and conjugates thereof

Similar Documents

Publication Publication Date Title
US12291576B2 (en) Anti-CD45 antibodies and conjugates thereof
JP7709376B2 (ja) Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
TWI904109B (zh) 抗ｃｄ４５抗體及其結合物
KR20210086683A (ko) 동종이형 조혈 줄기 세포 이식 방법
US20240075157A1 (en) Fc silenced antibody drug conjugates (adcs) and uses thereof
CN112739340B (zh) 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
US20220062339A1 (en) Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy
JP2021530545A (ja) 同種異系の細胞療法における抗−ｃｄ２抗体薬物コンジュゲート（ａｄｃ）の使用
JPWO2020092654A5 (https=)
JP2025172753A (ja) 自己免疫疾患を治療するための方法および組成物
JP2022529727A5 (https=)
CN112739339B (zh) 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
CN115397444A (zh) 用于同种异体移植的组合物和方法
JPWO2020146432A5 (https=)
JPWO2020219748A5 (https=)